Table 1.
Detailed patient characteristics of all patients with classical Hodgkin lymphoma and peripheral T‐cell lymphoma
| cHL | PTCL | |
|---|---|---|
| n = 28 | n = 5 | |
| Sex | ||
| Male | 64.3% (18) | 60.0% (3) |
| Female | 35.7% (10) | 40.0% (2) |
| Age at primary diagnosis (y) | ||
| Median | 35.5 | 74 |
| Mean ± SD | 40.45 ± 20.80 | 67.80 ± 10.11 |
| Range | 9‐84 | 54‐76 |
| Age at start bendamustine + BV (y) | ||
| Median | 43.5 | 75 |
| Mean ± SD | 46.21 ± 19.36 | 69.40 ± 9.86 |
| Range | 21‐84 | 54‐77 |
| Bendamustine + BV treatment line | ||
| First‐line | 14.3% (4) | 20.0% (1) |
| Second‐line | 42.9% (12) | 60.0% (3) |
| Third‐line | 32.1% (9) | 20.0% (1) |
| Fourth‐line | 3.6% (1) | – |
| Fifth‐line | 7.1% (2) | – |
| ECOG before bendamustine + BV | ||
| 0 | 46.4% (13) | 80.0% (4) |
| 1 | 42.9% (12) | 20.0% (1) |
| 2 | 7.1% (2) | – |
| Missing | 3.6% (1) | – |
| Response to bendamustine + BV | ||
| Overall response rate | 100% (28) | 60.0% (3) |
| Complete remission | 78.6% (22) | 40.0% (2) |
| Partial remission | 21.4% (6) | 20.0% (1) |
| No response | – | 50.0% (2) |
| Bendamustine + BV as induction before ASCT | ||
| Yes | 46.4% (13) | – |
| No | 53.6% (15) | 100.0% (5) |
| Stem cell collection during therapy | ||
| Planned | 9 (69.2% of ASCT) | – |
| Successful | 9 (100%) | – |
| BV maintenance given | ||
| No | 67.9% (19) | 80.0% (4) |
| Yes | 32.1% (9) | 20.0% (1) |
| Documented adverse events | ||
| Infections (any grade) | 35.7% (10) | 40.0% (2) |
| Neutropenia (±fever) necessitating G‐CSF | 10.7% (3) | 40.0% (2) |
| Skin‐related adverse events | 39.3% (11) | – |
| Peripheral polyneuropathy | 10.7% (3) | – |
| Infusion‐related reactions | 35.7% (10) | – |
| Therapy delay | 21.4% (6) | – |
| Dose reduction | 28.6% (8) | 20.0% (1) |
| Death during therapy | 3.6% (1) | 20.0% (1) |
Abbreviations: ASCT, autologous stem cell transplantation; BV, brentuximab vedotin; cHL, classical Hodgkin lymphoma; G‐CSF, granulocyte‐colony‐stimulating factor; PTCL, peripheral T‐cell lymphoma; SD, standard deviation.